Small Cap Stocks Sport Chalet NASDAQ

Small Cap Stocks Sport Chalet NASDAQ

Sport Chalet (NASDAQ: SPCHB), ICO Inc. (NASDAQ: ICOC), Ultra Clean Holdings (NASDAQ: UCTT) and QLT Inc. (NASDAQ: QLTI) start the week in plus territory.

Following its best week in four months, the Dow rose this morning in early trading and the bulls extended their gains into a new week. Hopefully this week will be as strong for Small Cap Stocks as it was last week. One can only hope.

Small Caps Sport Chalet NASDAQ: SPCHB, ICO Inc. NASDAQ: ICOC, Ultra Clean Holdings NASDAQ: UCTT and QLT Inc. NASDAQ: QLTI all came roaring out of the gate this morning. If buyers are aggregating at this price point (around $5.86 a share this morning), the stock could hold this area as its lowend threshold going forward. BCRX was up 45% Friday to close at $6.08. EST today, more than half its 3Month average daily trading volume. Now trading in the $3.90 range with a new market cap of $55 million, SPCHB had doubled its 3Month average daily trading volume this morning and I believe that's due to some of the very aggressive steps the company took in May to tighten its belt and become more effective in its primary markets of California, Nevada, Arizona, and Utah.

One step SPCHB took was getting a handle on its inventory and lowering the amount of winter apparel held, while from January through May, receiving a total of $138.6 million in fresh inventory for the summer. Good move.

SPCHB offers over 50 services for the serious sports enthusiast, including backpacking, canyoneering, and kayaking instruction, custom golf club fitting and repair, snowboard and ski rental and repair, Scuba training and certification, Scuba boat charters, racquet stringing, and bicycle tuneup and repair throughout its 55 locations.

At $3.90, SPCHB is below its 52week high of $4.52 set on 061209 and far above its 52week low of $0.40 set on 040709. At $3.90, SPCHB is above both its 50day and 200day moving averages. SPCHB has trailing twelve month revenues of $14.12 million.

With skiseason due up three months, and considering SPCHB has remodeled its financing and inventory structure, the stock could move higher as the recession resides. EST.

With 20 locations in 9 countries, ICOC produces custom polymer powders for the textile, metal coating and masterbatch markets. ICOC is also expanding into Africa and Asia. Its typical customers are in oil exploration, plastics and chemicals. As the world gets back to producing, it will need; plastic, chemicals and metals. You get the idea.

At $3.13, ICOC is less than half its 52week high of $6.72 set on 092208 and triple its 52week low of $1.03 set on 030609 (a good buy signal). At $3.13, ICOC is ahead of both its 50day and 200day moving average. ICOC has trailing twelve month revenues of $373.20 million. Trading is brisk on this stock. UCTT has a 3Month average daily trading volume of 146, 942 shares.

UCTT develops and supplies critical delivery subsystems to OEM manufacturers of semiconductor capital equipment in North America, Europe, and Asia. UCTT provides all the hardware you see in those 'clean rooms' and assembly lines on television. UCTT has a supply chain pipeline that is established and can rapidly expand. Impressive.

At $3.33 a share, UCTT is far below its 52week high of $8.81 set on 082509 and is well above its 52week low of $0.78 set on 030309. At $3.33, UCTT is above both its 50day and 200day moving average. UCTT has trailing twelve month revenues of $196 million. UCTT's share out versus float ratio is nearparity. QLTI picked up over 7% ($0.17) in early trading. QLTI is currently trading in the $2.50 range with a new market cap of $136 million. QLTI picked up half of its 3Month average daily trading volume of 245,008 shares by midmorning.

QLTI is a biopharmaceutical company that engages in the discovery, development, and commercialization of pharmaceutical products, primarily in the field of ophthalmology. QLTI products in development include Visudyne therapy; punctal plug drug delivery system, an invasive drug delivery system for delivering various drugs topically to the eye through controlled sustained release to the tear film, under Phase II studies targeting the treatment of glaucoma and ocular hypertension; and QLT091001, a Phase Ia orally administered synthetic retinoid replacement therapy for 11cisretinal, which is a key biochemical component of the visual retinoid cycle.

At $2.50, QLTI is below its 52week high of $4.09 set on 090808 and above its 52week low of $1.40 set on 031209 (again, a good buy signal). At $2.50, QLTI is above both its 50day and 200day moving averages. QLTI has trailing twelve month Revenues of $54 million. QLTI's shares out versus float ratio is a bit lopsided. I would like to see more shares in the QLTI float.